1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsBridging Interventional Development Gaps (BrIDGs) Program is sponsored by National Center for Advancing Translational Sciences (NCATS). Partners with researchers to advance promising therapeutic agents through late-stage preclinical development toward clinical testing.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Bridging Interventional Development Gaps (BrIDGs) | National Center for Advancing Translational Sciences U.S. Department of Health & Human Services National Institutes of Health The Bridging Interventional Development Gaps (BrIDGs) program helps researchers in advancing promising therapeutic agents through late-stage preclinical development toward an Investigational New Drug (IND) application and clinical testing.
The BrIDGs program allows research partnerships to advance candidate therapeutics for both common and rare diseases into clinical testing. Investigators do not receive grant funds through this program.
Instead, selected researchers partner with NCATS experts to generate preclinical data and clinical-grade material through government contracts for use in Investigational New Drug (IND) applications to a regulatory branch of authority, such as the U.S. Food and Drug Administration (FDA). The high cost of translating therapeutic discoveries into clinically available agents can delay the development of promising therapies.
Researchers may partner with private-sector companies to advance projects with significant commercial potential, but high-risk ideas or therapies for uncommon disorders frequently do not attract investors. When private-sector resources are limited, BrIDGs research and development expertise and services can help researchers bridge the gap between the preclinical and clinical stages of therapeutic development.
This support allows continued evaluation of agents that may improve the standard of care for patients with a variety of diseases and disorders. BrIDGs forms partnerships with researchers from academia, nonprofit organizations and pharmaceutical and biotechnology companies to complete preclinical development for promising therapeutic candidates. Contact us to learn more about working with us.
Drug Repurposing Market Turning Failures into Breakthroughs at 4. 9% CAGR by 2032 | Maximize Market Research Drug Repurposing Market Turning Failures into Breakthroughs at 4.
9% CAGR by 2032 | Maximize Market Research May 5, 2026 - Media Coverage Bridging Interventional Development Gaps (BrIDGs) Therapeutics for Rare and Neglected Diseases (TRND) How Academic Researchers Can Use Patent Data to Fuel Drug Repositioning Research How Academic Researchers Can Use Patent Data to Fuel Drug Repositioning Research December 17, 2025 - Grantee/Partner News Bridging Interventional Development Gaps (BrIDGs) Our Impact on Drug Discovery and Development Bespoke Gene Therapy Consortium (BGTC) We help lead this public-private partnership program that focuses on developing platforms and standards to speed the development and delivery of gene therapies for rare diseases.
Platform Vector Gene Therapy (PaVe-GT) Our pilot project is testing the feasibility of increasing the efficiency of gene therapy clinical trials by using the same gene delivery system and manufacturing methods for multiple gene therapies. Chemistry Technologies Development Our chemistry technology experts develop small molecules and screening methods that can be used by other scientists to drive innovations in therapeutic development.
Last updated on July 18, 2025
According to the current listing, eligibility includes: Open to researchers from academia, nonprofit organizations, and pharmaceutical/biotechnology companies; investigators partner with NCATS rather than receive direct grant funds. Confirm the full requirements in the official notice before applying.
Bridging Interventional Development Gaps (BrIDGs) Program is funded by National Center for Advancing Translational Sciences (NCATS). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleDRL's Advancing Labor Rights in the Garment Industry opportunity (DFOP0019477) offers exactly $986,500 — floor and ceiling identical — for a single 24-month award. Eligibility is scoped to countries with signed Agreements on Reciprocal Trade with the United States, and Bangladesh is explicitly excluded. That design tells you more about the program than the funding amount does.
Read articleSchmidt Sciences opened a 'Scaling AI Safety for a Multi-Agent World' program with awards up to $1 million and an August 8, 2026 deadline. Against a backdrop of federal research slowdowns, here is why private science philanthropy matters more than ever, how these funders differ from federal agencies, and how researchers should approach them.
Read article